MX2021002655A - Terapia de combinacion para el tratamiento de enfermedad hepatica. - Google Patents

Terapia de combinacion para el tratamiento de enfermedad hepatica.

Info

Publication number
MX2021002655A
MX2021002655A MX2021002655A MX2021002655A MX2021002655A MX 2021002655 A MX2021002655 A MX 2021002655A MX 2021002655 A MX2021002655 A MX 2021002655A MX 2021002655 A MX2021002655 A MX 2021002655A MX 2021002655 A MX2021002655 A MX 2021002655A
Authority
MX
Mexico
Prior art keywords
liver disease
treatment
combination therapy
pharmaceutical compositions
thyroid hormone
Prior art date
Application number
MX2021002655A
Other languages
English (en)
Inventor
Tali Gorfine
Allen Baharaff
Liat Hayardeny-Nissimov
Original Assignee
Galmed Res And Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Res And Development Ltd filed Critical Galmed Res And Development Ltd
Publication of MX2021002655A publication Critical patent/MX2021002655A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas, y más específicamente a composiciones farmacéuticas que comprenden al menos un conjugado de ácido grasoácido biliar y al menos un agonista del receptor de la hormona tiroidea o un mimético de la hormona tiroidea o sales farmacéuticamente aceptables de los mismos, y al uso de tales composiciones en métodos para tratar, estabilizar o disminuir la gravedad o la progresión de una enfermedad hepática, incluyendo fibrosis, enfermedad del hígado graso no alcohólico (NAFLD), esteatohepatitis no alcohólica (NASH) y comorbilidades asociadas con una enfermedad hepática.
MX2021002655A 2018-09-06 2019-09-03 Terapia de combinacion para el tratamiento de enfermedad hepatica. MX2021002655A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862727565P 2018-09-06 2018-09-06
PCT/IL2019/050983 WO2020049556A1 (en) 2018-09-06 2019-09-03 Combination therapy for the treatment of liver disease

Publications (1)

Publication Number Publication Date
MX2021002655A true MX2021002655A (es) 2021-05-27

Family

ID=69722275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002655A MX2021002655A (es) 2018-09-06 2019-09-03 Terapia de combinacion para el tratamiento de enfermedad hepatica.

Country Status (12)

Country Link
US (1) US20210338826A1 (es)
EP (1) EP3846821B1 (es)
JP (1) JP2022500366A (es)
KR (1) KR20210057758A (es)
CN (1) CN113164498A (es)
AU (1) AU2019334939A1 (es)
BR (1) BR112021004140A2 (es)
CA (1) CA3111025C (es)
IL (1) IL281244A (es)
MA (1) MA53562A (es)
MX (1) MX2021002655A (es)
WO (1) WO2020049556A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2021204751A1 (en) * 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480524T1 (de) * 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
KR20170102299A (ko) * 2015-01-09 2017-09-08 길리어드 아폴로, 엘엘씨 비-알콜성 지방간 질환의 치료를 위한 acc 억제제 조합 요법
WO2018075650A1 (en) * 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
US11197870B2 (en) * 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis

Also Published As

Publication number Publication date
WO2020049556A1 (en) 2020-03-12
MA53562A (fr) 2021-07-14
AU2019334939A1 (en) 2021-04-29
CN113164498A (zh) 2021-07-23
BR112021004140A2 (pt) 2021-05-25
KR20210057758A (ko) 2021-05-21
CA3111025A1 (en) 2020-03-12
US20210338826A1 (en) 2021-11-04
EP3846821A4 (en) 2022-05-25
CA3111025C (en) 2023-10-31
EP3846821B1 (en) 2023-10-04
IL281244A (en) 2021-04-29
EP3846821A1 (en) 2021-07-14
JP2022500366A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
MX2022007012A (es) Uso de un agonista doble del receptor de glp-1/glucagon de larga accion para el tratamiento de la enfermedad de higado graso no alcoholico.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2019012884A (es) Terapia de combinacion.
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
WO2012112626A3 (en) Compositions, devices and methods of use thereof for the treatment of cancers
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
NZ751746A (en) Combination therapy with controlled-release cnp agonists
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
MX2019003889A (es) Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
PH12019501528A1 (en) Combination therapy for nonalcoholic steatohepatitis (nash) and liver fibrosis
MX2019005730A (es) Metodo para tratar enfermedad de almacenamiento de glucogeno.
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
PH12019500326A1 (en) Combination of fxr agonists
MX2021001272A (es) Composiciones de bismuto-tiol y metodos de uso.
WO2016168553A8 (en) Deuterated obeticholic acid
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
PH12018000207B1 (en) A pharmaceutical composition for prevention of diet induced obesity
MX2022007929A (es) Coagonistas de triazol grapados de los receptores de glucagon y glp-1.
MX2022013230A (es) Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis.
MX2018007377A (es) Composicion de acido hialuronico para inyecciones en el pene.
MX2022007926A (es) Coagonistas lactamicos grapados de los receptores de glucagon y glp-1.